A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
The new oral therapy demonstrates superior lesion healing for complex patients who have few current treatment options.
Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research. An ...
Fred Hutch virologists eliminated at least 90% of HSV-1 in preclinical models of oral and genital herpes and reduced viral shedding in a study published in Nature Communications SEATTLE — May 13, 2024 ...
Hosted on MSN
Why Hasn't Herpes Treatment Advanced in 40 Years?
Approximately two-thirds of the world's population under the age of 50 years have oral or genital herpes simplex type 1 (HSV-1) infection, while one in eight have herpes simplex type 2 (HSV-2) ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research. An ...
SEATTLE — May 13, 2024 — Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results